Neurological Surgery Doctors in Corpus Christi, TX Accepting Medicare

5 Neurological Surgery doctors found. Showing 1 - 5

Dr. Paul James Schmitt, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2606 Hospital Blvd Ste E, Corpus Christi, TX 78405 Phone: 361-902-4780

Dr. Mathew Thomas Alexander, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1227 3rd St, Corpus Christi, TX 78404 Phone: 361-883-4323    Fax: 361-883-4324

Dr. Stefan J Konasiewicz, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1227 3rd St, Corpus Christi, TX 78404 Phone: 361-883-4323    Fax: 361-883-4324

Dr. Ashley K Hanna, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 3533 S Alameda St, Corpus Christi, TX 78411 Phone: 361-694-4700

Patrick Langham Gleason, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1227 3rd St, Corpus Christi, TX 78404 Phone: 361-883-4323    Fax: 361-883-8216

News Archive

Research examines molecules derived from ticks as potential COVID-19 treatment option

UK-based biotechnology firm ILC Therapeutics is working alongside the University of Oxford to examine the use of Evasins – molecules derived from ticks – as a potential COVID-19 treatment option for patients whose lungs are badly damaged by the virus and face a critical juncture in recovery.

Doctors, nurses and urgent care centers address increasing demand

The (Lynchburg, Va.) News and Advance reports on doctor shortages in Virginia: "Attracting more physicians to the area, and keeping them, is a challenge that has become more urgent. So much so that Centra is in the midst of creating a formal Physician Recruiting Office, where staff will work to convince physicians to consider coming to Lynchburg for their residency or to practice.

Study links verbal aggression to prenatal testosterone exposure

A new study in the Journal of Communication links verbal aggression to prenatal testosterone exposure. The lead researcher, at University at Buffalo - The State University of New York, used the 2D:4D measure to predict verbal aggression.

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND's broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.

Dietary carbohydrates linked to increased risk of osteoarthritis

Do your knees ache? According to new findings from the Oklahoma Medical Research Foundation, your diet could be a culprit.

Read more Medical News

› Verified 7 days ago